Microbiotica, a clinical-stage biopharma company, has announced the dosing of the first patient in its Phase 1b First-in-Human trial, COMPOSER-1, for MB310 in ulcerative colitis ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback